Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
Colorcon
Mallinckrodt
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR CALCITRIOL


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Calcitriol

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00055263 ↗ A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies Completed Novacea Phase 1 2002-03-01 The purposes of this study are to: - Test the safety of DN-101 in patients with advanced malignancies - Understand how fast the body absorbs, processes, and eliminates DN-101 - Determine the highest dose of DN-101 that is well tolerated by cancer patients - Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the approved product
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Calcitriol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed Merck Sharp & Dohme Corp. Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗ Osteoporosis Prevention After Heart Transplant Completed Columbia University Phase 3 1997-09-01 During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Calcitriol

Condition Name

Condition Name for Calcitriol
Intervention Trials
Vitamin D Deficiency 11
Prostate Cancer 10
Chronic Kidney Disease 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Calcitriol
Intervention Trials
Kidney Diseases 31
Renal Insufficiency, Chronic 21
Hyperparathyroidism 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Calcitriol

Trials by Country

Trials by Country for Calcitriol
Location Trials
United States 261
Canada 24
China 8
Italy 7
Malaysia 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Calcitriol
Location Trials
New York 32
California 18
Texas 15
Pennsylvania 12
Oregon 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Calcitriol

Clinical Trial Phase

Clinical Trial Phase for Calcitriol
Clinical Trial Phase Trials
Phase 4 39
Phase 3 17
Phase 2/Phase 3 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Calcitriol
Clinical Trial Phase Trials
Completed 92
Unknown status 28
Terminated 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Calcitriol

Sponsor Name

Sponsor Name for Calcitriol
Sponsor Trials
National Cancer Institute (NCI) 12
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 8
Novacea 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Calcitriol
Sponsor Trials
Other 167
Industry 54
NIH 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Medtronic
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.